Issue Date: July 24, 2017
Merck to pay Gilead’s lawyer fees
A California federal judge has ordered Merck & Co. to pay Gilead Sciences $14 million in attorney fees in a case involving Gilead’s Sovaldi and Harvoni hepatitis C virus treatments. In June 2016, the judge overturned a $200 million jury award Merck had won in a patent infringement dispute involving sofosbuvir, an active ingredient in both drugs, after she determined Merck had lied. In December 2016, Merck won a $2.5 billion jury award from Gilead in a separate patent dispute involving the hepatitis C drugs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society